Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 19Active not recruiting 19Completed 3Terminated 2Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Breast Neoplasms 1

Interventions

pembrolizumab 11Nivolumab 6fludarabine phosphate 5fludarabine 5Paclitaxel 5Cyclophosphamide 5Cisplatin 5Cetuximab 5Carboplatin 5atezolizumab 4Specimen Handling 4Pemetrexed 4Docetaxel 4Bevacizumab 4durvalumab 3Magnetic Resonance Spectroscopy 3Ipilimumab 3venetoclax 2temsirolimus 2niraparib 2ibrutinib 2enzalutamide 2encorafenib 2binimetinib 2Trastuzumab 2Taxes 2Standard of Care 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Platinum × 30 days × Clear all
NCT06351332 2026-06-04

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Dana-Farber Cancer Institute

Phase 1 Terminated
7 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04158141 2026-05-19

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

NRG Oncology

Phase 3 Terminated
16 enrolled 18 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡